Q-omics provides the consensus-scored PPP2CA profile across patient tissues and cancer cell-line models. PPP2CA expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PPP2CA is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, PPP2CA RNA expression shows 19,108 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, THCA, and ACC as cancer lineages where PPP2CA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPP2CA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPP2CA survival associations across molecular data types. PPP2CA RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPP2CA RNA expression–survival associations across cancer types. High PPP2CA expression shows unfavorable associations in HNSC, LIHC, UVM, PAAD and CESC, but favorable associations in KIRC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for PPP2CA RNA expression.
This table summarizes PPP2CA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PPP2CA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPP2CA shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC, BRCA, CHOL and HNSC. The THCA box plot shows higher PPP2CA RNA expression in normal versus tumor tissue (log2 FC = −0.340, t-test p < 0.001).
This table shows molecular features associated with PPP2CA in patient tissues and cancer cell lines. In patient samples, PPP2CA shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PPP2CA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
